Cl de Peau Beaut Renews Global Partnership with UNICEF, Aiming to Reach an Additional 7.3 Million Girls
TOKYO, April 16, 2026 /PRNewswire/ -- Clé de Peau Beauté announced the…
Basilea awarded additional CARB-X funding of USD6million to support the clinical development of antibiotic BAL2420
Funding is awarded following successful completion of IND-enabling studies and clinical study…
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
April 06, 2026 10:53 ET | Source: Celldex Therapeutics, Inc. HAMPTON, N.J.,…
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON”…
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142)…
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful…
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
February 28, 2026 09:45 ET | Source: Cogent Biosciences, Inc. Bezuclastinib mean…
Cango Inc. Closed the US$10.5 Million Equity Investment and Secured US$65 Million Additional Equity Investments
DALLAS, Feb. 12, 2026 /PRNewswire/ -- Cango Inc. (NYSE: CANG) ("Cango" or…
Banqup secures additional shareholder funding, recalibrates covenants with Francisco Partners and signs an agreement for the sale of Baltic operations
Press Release - Inside Information La Hulpe, Belgium –26 January 2026, 7:00…
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
January 23, 2026 17:00 ET | Source: Corvus Pharmaceuticals, Inc. SOUTH SAN…
